1-6 of 6
Hervé Besson
Close
Sort by
Journal Articles

Single-Agent Ibrutinib vs Real-World (RW) Treatments for Patients with Chronic Lymphocytic Leukemia (CLL) and del11q: Adjusted Comparison of RESONATE-2 TM and RESONATE TM with RW Databases

Gilles Andre Salles, MD, Evelyne Callet-Bauchu, Hervé Besson, Margaret Doyle, Jamie Garside, Martin Spacek, Michael Doubek, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4427.
https://doi.org/10.1182/blood-2018-99-112172
Published: 2018
Journal Articles

Efficacy of Ibrutinib-Rituximab versus Real-World (RW) Treatments for Patients with Waldenström's Macroglobulinemia (WM): Adjusted Comparison of iNNOVATE and the Lyon-Sud RW Database

Lionel Karlin, MD, Hervé Besson, Christoph Tapprich, Jamie Garside, Gilles Salles
Journal: Blood
Blood (2018) 132 (Supplement 1): 1604.
https://doi.org/10.1182/blood-2018-99-112203
Published: 2018
Journal Articles

Single-Agent Ibrutinib Versus Real-World Treatments for Patients with Treatment-Naïve Chronic Lymphocytic Leukemia: Adjusted Comparison of Resonate-2™ with Real-World Databases

Gilles Salles, MD PhD, Lukas Smolej, MD PhD, Emmanuel Bachy, Lucile Baseggio, MD, Hervé Besson, Ruben Hermans, Nollaig Healy, Jamie Garside, Wafae Iraqi, Joris Diels, Finlay MacDougall, Corinna Pick-Lauer, Martin Spacek, Renata Urbanova, Daniel Lysak, Evelyne Callet-Bauchu, Michael Doubek, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5342.
https://doi.org/10.1182/blood.V130.Suppl_1.5342.5342
Published: 2017
Journal Articles

Comparative Effectiveness of Single-Agent Ibrutinib in the Ray Trial Versus Real-World Treatment in the Lyon-Sud Database in Patients with Relapsed or Refractory Mantle Cell Lymphoma

Clementine Sarkozy, MD, Alexandra Traverse-Glehen, MD PhD, Emmanuel Bachy, Lionel Karlin, MD, Hervé Ghesquières, MD PhD, Hervé Besson, Ruben Hermans, Nollaig Healy, Jamie Garside, Joris Diels, Finlay MacDougall, Corinna Pick-Lauer, Gilles Salles, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2770.
https://doi.org/10.1182/blood.V130.Suppl_1.2770.2770
Published: 2017
Journal Articles

Comparative Effectiveness of Daratumumab Monotherapy Versus a Real-World Historical Control from the Czech Republic in Heavily Pretreated and Highly Refractory Multiple Myeloma Patients

Roman Hájek, Tomas Jelinek, MD, Vladimir Maisnar, MD PhD, Ludek Pour, Ivan Spicka, MD PhD, Jiri Minarik, MD PhD, Evzen Gregora, MD, Petr Kessler, MD, Michal Sykora, MD, Hana Frankova, MD, Dagmar Adamova, MD, Marek Wróbel, Peter Mikula, MD, Jiri Jarkovsky, MSc, PhD, Xenia Gatopoulou, Sarka Vesela, Joris Diels, PhD, Hervé Besson, PhD, Lucie Brozova, MSc, Tetsuro Ito
Journal: Blood
Blood (2016) 128 (22): 3332.
https://doi.org/10.1182/blood.V128.22.3332.3332
Published: 2016
Journal Articles

Single-Agent Ibrutinib Vs Standard of Care for Patients with Relapsed/Refractory (R/R) and Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL): An Adjusted Comparison of RESONATE TM and RESONATE-2 TM with the French Lyon-Sud Database

Gilles A. Salles, Lucile Baseggio, PharmD, PhD, Emmanuel Bachy, MD PhD, Clementine Sarkozy, MD, Herve Ghesquieres, MD PhD, Joris Diels, PhD, Hervé Besson, PhD, Finlay MacDougall, BA, Ruben Hermans, PhD MSc, Nollaig Healy, PhD, Jamie Garside, MSc, Wafae Iraqi, PharmD, PhD, Evelyne Callet-Bauchu, MD PhD
Journal: Blood
Blood (2016) 128 (22): 2039.
https://doi.org/10.1182/blood.V128.22.2039.2039
Published: 2016